Eisai Innovation, Inc.

About The Fund

Eisai Innovation, Inc. is a strategic investment organization established to foster synergy between the scientific community and the Eisai network of companies. With a global investment reach that includes the US, Europe, Japan, China, and emerging markets including Africa, their focus is on contributing to human health care by prioritizing disease prevention, prediction, and treatment through global investments and research collaboration. Eisai Innovation strategically positions itself to help create a world free from the fear and pain of disease, make predictions about future diseases, consider sustainable development goals for healthcare, and acquire innovative assets and businesses. Their investment thesis targets the neurology and oncology sectors, including their digital solutions, as well as diagnostics, with a typical investment size of around $5 million. The firm aspires to lead Eisai into the top 10 healthcare companies through collaborations with biotech and digital health companies and through mergers and acquisitions. They aim to establish a full-scale global Corporate Venture Investment capability, enabling Eisai to take a leadership position in supporting academic-established startups. Additionally, keeping up with the latest research in cutting-edge technologies, drug modalities, and digital healthcare solutions enables Eisai to formulate near- and long-term strategies. Their investments also serve to foster top talent, translating newly obtained knowledge into actionable strategies. These efforts are spearheaded by a team with deep expertise in biology, neuroscience, and business development, including Yoshiharu Mizui, Kou Qin, and Paul Wu. The investment fund has defined minimum, maximum, and sweet spot investment amounts at $100,000, $5,000,000, and $1,500,000, respectively, and they specialize in Seed, Series A, and Series B funding stages. Eisai Innovation, Inc. was founded by Yoshiharu Mizui, a veteran in oncology research and business strategy. The firm operates offices in Cambridge, MA, and San Francisco, CA and welcomes collaboration and investment inquiries through their email contact.